Page last updated: 2024-12-05

sulfaguanidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sulfaguanidine is a sulfonamide antimicrobial drug that was first synthesized in the 1940s. It is effective against a range of gram-negative bacteria, including Escherichia coli and Salmonella species. Sulfaguanidine works by inhibiting the synthesis of dihydrofolic acid, which is an essential precursor for bacterial DNA, RNA, and protein synthesis. It is primarily used in the treatment of bacterial infections of the gastrointestinal tract, such as traveler's diarrhea and bacillary dysentery. Sulfaguanidine is poorly absorbed from the gastrointestinal tract, allowing it to reach high concentrations in the gut lumen. Due to its limited systemic absorption, it has a low risk of causing adverse effects. Sulfaguanidine is still used in veterinary medicine for the treatment of intestinal infections in animals. However, the use of sulfaguanidine in human medicine has decreased due to the availability of other more effective and safer antimicrobial drugs. Research on sulfaguanidine continues to focus on its potential applications in the prevention and treatment of gastrointestinal infections, particularly in developing countries where access to newer drugs is limited.'

Sulfaguanidine: A sulfanilamide antimicrobial agent that is used to treat enteric infections. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sulfaguanidine : A sulfonamide incorporating a guanidine moiety used to block the synthesis of folic acid; mostly used in veterinary medicine [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5324
CHEMBL ID338802
CHEBI ID94621
SCHEMBL ID93639
SCHEMBL ID93640
MeSH IDM0020744

Synonyms (203)

Synonym
6190-55-2
DIVK1C_000633
KBIO1_000633
PRESTWICK2_000010
4-amino-n-[amino(imino)methyl]benzenesulfonamide
SPECTRUM_001412
57-67-0
guanidine, sulfanilyl-
ruocid
emerin (pharmaceutical)
sulgin
p-aminobenzenesulfoguanidide
benzenesulfonamide, 4-amino-n-(aminoiminomethyl)-
abiguanil
rp 2275
[(p-aminophenyl)sulfonyl]guanidine
sulfentidine
1-[(p-aminophenyl)sulfonyl]guanidine
orgaguanidon
sulfaguanidin
aterian
a-307
sulfoguanil
resulfon
s-guanidine
sulfaguine
ganidan
guanicil
sulfaguamidine
sulfoguenil
sulfanilguanidine
sulfanilamide, n(sup1)-amidino-
n-guanylsulfanilamide
sulfoquanidine
guamide
sulfoguanyl
sulfaguanidine
suganyl
nsc-14041
nsc14041
n1-amidinosulfanilamide
guanidan
1-sulfanilylguanidine
p-aminobenzenesulfonylguanidine
sulfoguanidine
diacta
n(sup1)-amidinosulfanilamide
[(4-aminophenyl)sulfonyl]guanidine
n(sup1)-guanylsulfanilamide
wln: zr dswmyzum
sulfanilylguanidine
sulfaguanil
sulfanilamide, n1-amidino-
PRESTWICK_429
NCGC00016252-01
cas-57-67-0
PRESTWICK3_000010
1-(4-aminophenyl)sulfonylguanidine
IDI1_000633
SPECTRUM5_001197
BSPBIO_000019
AB00052220
D02437
sulfaguanidine (inn)
NCGC00024191-03
NCGC00024191-04
benzenesulfonamide, 4-amino-n-(diaminomethylene)-
sulfanilamide, n(sup 1)-amidino-
sulginum
sulfaguanidinum [inn-latin]
n(sup 1)-(diaminomethylene)sulfanilamide
n(sup 1)-amidinosulfanilamide
shigatox
sulfaguanidine [inn]
emerin (pharmaceutical) (van)
einecs 200-345-9
n-p-aminobenzenesulphonylguanidine monohydrate
sulphaguanidine
ai3-01048
solfaguanidina [dcit]
((p-aminophenyl)sulfonyl)guanidine
n(sup 1)-guanylsulfanilamide
((4-aminophenyl)sulfonyl)guanidine
4-amino-n-(diaminomethylene)benzenesulfonamide
1-((p-aminophenyl)sulfonyl)guanidine
sulfaguanidina [inn-spanish]
4-amino-n-(aminoiminomethyl)benzenesulfonamide
nsc 14041
MLS000069712
smr000058191
KBIO3_002451
KBIOSS_001892
KBIOGR_000758
KBIO2_001892
KBIO2_007028
KBIO2_004460
SPECTRUM3_001456
PRESTWICK1_000010
SPECTRUM4_000429
NINDS_000633
SPBIO_001500
SPECTRUM2_001420
PRESTWICK0_000010
SPBIO_001940
SPECTRUM1501146
SMP1_000283
BPBIO1_000021
BSPBIO_002951
NCGC00018234-01
STK031666
4-amino-n-carbamimidoylbenzenesulfonamide
AC-10943
HMS2092H05
AKOS000319495
CHEMBL338802 ,
HMS501P15
4-aminobenzenesulfonylguanidine
4-amino-n-amidinobenzenesulfonamide
HMS1568A21
HMS1921J19
2-(4-aminophenyl)sulfonylguanidine
1n-amino(imino)methyl-4-amino-1-benzenesulfonamide
4-amino-n-[(z)-amino(imino)methyl]benzenesulfonamide
4-amino-n-diaminomethylene-benzenesulfonamide
2-[(dioxidosulfanyl)amino]-1,9-dihydro-6h-purin-6-one[sulfaguanine]
4-amino-n-[(e)-amino(imino)methyl]benzenesulfonamide
bdbm50027795
AKOS000121440
4-amino-n-(diaminomethylidene)benzenesulfonamide
STK064640
NCGC00018234-03
NCGC00018234-05
NCGC00018234-02
NCGC00018234-04
HMS2095A21
amino[(4-aminophenyl)sulfonyl]carboxamidine
pharmakon1600-01501146
nsc757861
nsc-757861
dtxcid103609
tox21_110329
dtxsid1023609 ,
sulfaguanidinum
solfaguanidina
n1-guanylsulfanilamide
sulfaguanidina
S4175
CCG-38973
15xq8043fn ,
unii-15xq8043fn
sulfaguanidine [inn:ban:nf]
sulfaguanidine [mi]
sulfaguanidine [mart.]
sulfaguanidine [who-dd]
sulfaguanidine [ep impurity]
sulfadiazine impurity c [ep impurity]
sulfaguanidine [ep monograph]
sulfadimidine impurity c [ep impurity]
61116-95-8
SCHEMBL93639
SCHEMBL93640
4-amino-n-(amino-imino-methyl)-benzenesulfonamide
tox21_110329_1
NCGC00018234-07
CS-4677
W-105451
n1-guanidylsulfanilamide
1-amino-4-(([amino(imino)methyl]amino)sulfonyl)benzene #
4-aminophenylsulfonylguanidine
sulfanilamide, n1-(diaminomethylene)-
n-1-amidinosulfanilamide
n-(4-aminobenzenesulfonyl)guanidine
HY-B1267
2-sulfanilylguanidine
AB00052220_16
AB00052220_15
Z56758608
sr-01000000167
SR-01000000167-2
4-amino-n-carbamimidoylbenzene-1-sulfonamide
sulfaguanidine, vetranal(tm), analytical standard
CHEBI:94621
HMS3652J05
sulfaguanidine, european pharmacopoeia (ep) reference standard
SR-01000000167-3
SR-01000000167-4
SBI-0051658.P002
SBI-0051658.P003
HMS3712A21
SW196658-2
Q414886
DB13726
ulfaguanidine,(s)
8R-0841
{[amino(imino)methyl]amino}(4-aminophenyl)dioxo-lambda6-sulfane
A914921
F85238
sulfaguanidine 1000 microg/ml in acetonitrile
EN300-34321
n''-(4-aminobenzenesulfonyl)guanidine
qa9 ,
gtpl12639
2-[(4-aminobenzene)sulfonyl]guanidine

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Results show that SQO and SGD are more toxic to green algae and daphnids, respectively, than other veterinary sulfonamides (SAs) and that their mixtures have a less then additive interaction."( Evaluation of the aquatic toxicity of two veterinary sulfonamides using five test organisms.
De Liguoro, M; Di Leva, V; Faccio, E; Gallina, G; Pinto, G; Pollio, A, 2010
)
0.36

Bioavailability

ExcerptReferenceRelevance
" These results indicate that after administration of these suppositories the bioavailability of non-absorbable drugs was sufficiently improved by enhancing both the release rate from the suppositories and the rectal membrane permeability."( Improvement by adjuvants on the rectal bioavailability of non-absorbable drugs following administration of suppository.
Masada, M; Nadai, T; Nakanishi, K, 1990
)
0.28
" The absolute bioavailability (57."( Gastrointestinal absorption of sulfaguanidine in neonatal and adult rats.
Miyake, K; Mizuno, N; Morita, E; Nishikata, M, 1986
)
0.56
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" After administration of an oral dose of labeled cholesterol ((14)C or (3)H) and an intravenous dose of colloidal labeled cholesterol ((3)H or (14)C) the ratio of the two labels in plasma or whole blood 48 hr or more after dosing compared closely to the ratio of areas under the respective specific activity-time curves."( Validation of a dual-isotope plasma ratio method for measurement of cholesterol absorption in rats.
Hughes, LB; Zilversmit, DB, 1974
)
0.25
" The physicochemical properties of SAs, dosage and nature of the matrix are the factors mainly responsible for their distribution in the natural environment."( Sulfadimethoxine and sulfaguanidine: their sorption potential on natural soils.
Białk-Bielińska, A; Bielawska, A; Kołodziejska, M; Kumirska, J; Maszkowska, J; Mrozik, W; Palavinskas, R; Stepnowski, P, 2012
)
0.7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
sulfonamide antibioticA class of sulfonamides whose members generally have bacteriostatic antibiotic properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency6.30960.044717.8581100.0000AID485294
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency3.16230.707912.194339.8107AID720542
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency4.89750.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.03620.000214.376460.0339AID720691
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency7.07950.01789.637444.6684AID588834
gemininHomo sapiens (human)Potency0.92000.004611.374133.4983AID624296
lamin isoform A-delta10Homo sapiens (human)Potency0.01780.891312.067628.1838AID1487
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency1.58490.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ProthrombinHomo sapiens (human)Ki0.09500.00000.78469.0000AID211187
Carbonic anhydrase 2Homo sapiens (human)IC50 (µMol)100.00000.00021.10608.3000AID241604
Trypsin-1Homo sapiens (human)Ki1.35000.00001.76768.9000AID215365
Trypsin-2Homo sapiens (human)Ki1.35000.00430.94873.2900AID215365
Trypsin-3Homo sapiens (human)Ki1.35000.00430.94873.2900AID215365
Carbonic anhydrase 5A, mitochondrialHomo sapiens (human)IC50 (µMol)100.00000.02003.10819.4000AID241574
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein argonaute-2Homo sapiens (human)Kd49.00004.30004.30004.3000AID1682438
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (76)

Processvia Protein(s)Taxonomy
positive regulation of protein phosphorylationProthrombinHomo sapiens (human)
proteolysisProthrombinHomo sapiens (human)
acute-phase responseProthrombinHomo sapiens (human)
cell surface receptor signaling pathwayProthrombinHomo sapiens (human)
G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell population proliferationProthrombinHomo sapiens (human)
regulation of cell shapeProthrombinHomo sapiens (human)
response to woundingProthrombinHomo sapiens (human)
negative regulation of platelet activationProthrombinHomo sapiens (human)
platelet activationProthrombinHomo sapiens (human)
regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell growthProthrombinHomo sapiens (human)
positive regulation of insulin secretionProthrombinHomo sapiens (human)
positive regulation of collagen biosynthetic processProthrombinHomo sapiens (human)
fibrinolysisProthrombinHomo sapiens (human)
negative regulation of proteolysisProthrombinHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProthrombinHomo sapiens (human)
negative regulation of astrocyte differentiationProthrombinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolProthrombinHomo sapiens (human)
regulation of cytosolic calcium ion concentrationProthrombinHomo sapiens (human)
cytolysis by host of symbiont cellsProthrombinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProthrombinHomo sapiens (human)
negative regulation of fibrinolysisProthrombinHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideProthrombinHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumProthrombinHomo sapiens (human)
positive regulation of lipid kinase activityProthrombinHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseProthrombinHomo sapiens (human)
positive regulation of protein localization to nucleusProthrombinHomo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
ligand-gated ion channel signaling pathwayProthrombinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProthrombinHomo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
digestionTrypsin-1Homo sapiens (human)
extracellular matrix disassemblyTrypsin-1Homo sapiens (human)
proteolysisTrypsin-1Homo sapiens (human)
proteolysisTrypsin-2Homo sapiens (human)
digestionTrypsin-2Homo sapiens (human)
antimicrobial humoral responseTrypsin-2Homo sapiens (human)
extracellular matrix disassemblyTrypsin-2Homo sapiens (human)
positive regulation of cell growthTrypsin-2Homo sapiens (human)
collagen catabolic processTrypsin-2Homo sapiens (human)
positive regulation of cell adhesionTrypsin-2Homo sapiens (human)
proteolysisTrypsin-3Homo sapiens (human)
digestionTrypsin-3Homo sapiens (human)
antimicrobial humoral responseTrypsin-3Homo sapiens (human)
zymogen activationTrypsin-3Homo sapiens (human)
endothelial cell migrationTrypsin-3Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
translationProtein argonaute-2Homo sapiens (human)
translational initiationProtein argonaute-2Homo sapiens (human)
post-embryonic developmentProtein argonaute-2Homo sapiens (human)
RNA secondary structure unwindingProtein argonaute-2Homo sapiens (human)
miRNA metabolic processProtein argonaute-2Homo sapiens (human)
siRNA processingProtein argonaute-2Homo sapiens (human)
regulatory ncRNA-mediated gene silencingProtein argonaute-2Homo sapiens (human)
pre-miRNA processingProtein argonaute-2Homo sapiens (human)
P-body assemblyProtein argonaute-2Homo sapiens (human)
regulatory ncRNA-mediated post-transcriptional gene silencingProtein argonaute-2Homo sapiens (human)
miRNA processingProtein argonaute-2Homo sapiens (human)
miRNA-mediated gene silencing by inhibition of translationProtein argonaute-2Homo sapiens (human)
miRNA-mediated gene silencing by mRNA destabilizationProtein argonaute-2Homo sapiens (human)
negative regulation of amyloid precursor protein biosynthetic processProtein argonaute-2Homo sapiens (human)
positive regulation of translationProtein argonaute-2Homo sapiens (human)
positive regulation of angiogenesisProtein argonaute-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIProtein argonaute-2Homo sapiens (human)
negative regulation of translational initiationProtein argonaute-2Homo sapiens (human)
positive regulation of nuclear-transcribed mRNA poly(A) tail shorteningProtein argonaute-2Homo sapiens (human)
RISC complex assemblyProtein argonaute-2Homo sapiens (human)
regulation of synapse maturationProtein argonaute-2Homo sapiens (human)
siRNA-mediated gene silencing by mRNA destabilizationProtein argonaute-2Homo sapiens (human)
positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decayProtein argonaute-2Homo sapiens (human)
positive regulation of trophoblast cell migrationProtein argonaute-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (29)

Processvia Protein(s)Taxonomy
lipopolysaccharide bindingProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombinHomo sapiens (human)
signaling receptor bindingProthrombinHomo sapiens (human)
calcium ion bindingProthrombinHomo sapiens (human)
protein bindingProthrombinHomo sapiens (human)
growth factor activityProthrombinHomo sapiens (human)
heparin bindingProthrombinHomo sapiens (human)
thrombospondin receptor activityProthrombinHomo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
serine-type endopeptidase activityTrypsin-1Homo sapiens (human)
metal ion bindingTrypsin-1Homo sapiens (human)
metalloendopeptidase activityTrypsin-2Homo sapiens (human)
serine-type endopeptidase activityTrypsin-2Homo sapiens (human)
calcium ion bindingTrypsin-2Homo sapiens (human)
protein bindingTrypsin-2Homo sapiens (human)
serine-type peptidase activityTrypsin-2Homo sapiens (human)
serine-type endopeptidase activityTrypsin-3Homo sapiens (human)
calcium ion bindingTrypsin-3Homo sapiens (human)
protein bindingTrypsin-3Homo sapiens (human)
serine-type peptidase activityTrypsin-3Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
siRNA bindingProtein argonaute-2Homo sapiens (human)
RNA 7-methylguanosine cap bindingProtein argonaute-2Homo sapiens (human)
RNA polymerase II complex bindingProtein argonaute-2Homo sapiens (human)
core promoter sequence-specific DNA bindingProtein argonaute-2Homo sapiens (human)
RNA bindingProtein argonaute-2Homo sapiens (human)
double-stranded RNA bindingProtein argonaute-2Homo sapiens (human)
single-stranded RNA bindingProtein argonaute-2Homo sapiens (human)
translation initiation factor activityProtein argonaute-2Homo sapiens (human)
RNA endonuclease activityProtein argonaute-2Homo sapiens (human)
protein bindingProtein argonaute-2Homo sapiens (human)
siRNA bindingProtein argonaute-2Homo sapiens (human)
miRNA bindingProtein argonaute-2Homo sapiens (human)
mRNA 3'-UTR AU-rich region bindingProtein argonaute-2Homo sapiens (human)
metal ion bindingProtein argonaute-2Homo sapiens (human)
endoribonuclease activity, cleaving siRNA-paired mRNAProtein argonaute-2Homo sapiens (human)
endoribonuclease activity, cleaving miRNA-paired mRNAProtein argonaute-2Homo sapiens (human)
mRNA cap bindingProtein argonaute-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (29)

Processvia Protein(s)Taxonomy
external side of plasma membraneProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular regionProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
endoplasmic reticulum lumenProthrombinHomo sapiens (human)
Golgi lumenProthrombinHomo sapiens (human)
plasma membraneProthrombinHomo sapiens (human)
extracellular exosomeProthrombinHomo sapiens (human)
blood microparticleProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular regionTrypsin-1Homo sapiens (human)
collagen-containing extracellular matrixTrypsin-1Homo sapiens (human)
blood microparticleTrypsin-1Homo sapiens (human)
extracellular spaceTrypsin-1Homo sapiens (human)
extracellular regionTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
extracellular matrixTrypsin-2Homo sapiens (human)
azurophil granule lumenTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
extracellular regionTrypsin-3Homo sapiens (human)
extracellular spaceTrypsin-3Homo sapiens (human)
tertiary granule lumenTrypsin-3Homo sapiens (human)
extracellular spaceTrypsin-3Homo sapiens (human)
mitochondrial matrixCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
cytoplasmCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
mitochondrionCarbonic anhydrase 5A, mitochondrialHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
postsynapseProtein argonaute-2Homo sapiens (human)
glutamatergic synapseProtein argonaute-2Homo sapiens (human)
P-bodyProtein argonaute-2Homo sapiens (human)
nucleusProtein argonaute-2Homo sapiens (human)
nucleoplasmProtein argonaute-2Homo sapiens (human)
cytoplasmProtein argonaute-2Homo sapiens (human)
cytosolProtein argonaute-2Homo sapiens (human)
membraneProtein argonaute-2Homo sapiens (human)
dendriteProtein argonaute-2Homo sapiens (human)
cytoplasmic ribonucleoprotein granuleProtein argonaute-2Homo sapiens (human)
extracellular exosomeProtein argonaute-2Homo sapiens (human)
RISC-loading complexProtein argonaute-2Homo sapiens (human)
RISC complexProtein argonaute-2Homo sapiens (human)
nucleusProtein argonaute-2Homo sapiens (human)
cytoplasmProtein argonaute-2Homo sapiens (human)
cytoplasmic ribonucleoprotein granuleProtein argonaute-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (90)

Assay IDTitleYearJournalArticle
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID211187Inhibitory activity against human thrombin (using Chromozym TH as the substrate)2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Protease inhibitors: synthesis and QSAR study of novel classes of nonbasic thrombin inhibitors incorporating sulfonylguanidine and O-methylsulfonylisourea moieties at P1.
AID13311Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID289692Antibacterial activity against Pasteurella multocida at 20 mg/ml by paper disc method2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID55868In vitro inhibition of Escherichia coli (K12J53) growth.1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID40934Antibacterial activity against Bacillus subtilis at a concentration of 80 ug/mL; no data2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID289690Antibacterial activity against Salmonella enteritidis at 30 mg/ml by paper disc method2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID253058Antibacterial activity of compound against Bacillus subtilis at 40 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID253056Antibacterial activity of compound against Bacillus subtilis at 10 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID70302Antibacterial activity against Escherichia coli at a concentration of 10 ug/mL; no data2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID289693Antibacterial activity against Pasteurella multocida at 30 mg/ml by paper disc method2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID70308Antibacterial activity against Escherichia coli at a concentration of 80 ug/mL; no data2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID26320pKa value is evaluated1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID253059Antibacterial activity of compound against Bacillus subtilis at 80 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID1682439Binding affinity to human Argonaut protein 2 PAZ domain assessed as change in enthalpy by isothermal titration microcalorimetry2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Sulfonamide antibiotics inhibit RNAi by binding to human Argonaute protein 2 PAZ.
AID94080Antibacterial activity against Klebsiella pneumoniae at a concentration of 120 ug/mL; no data2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID1682438Binding affinity to human Argonaut protein 2 PAZ domain assessed as dissociation constant by using isothermal titration microcalorimetry2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Sulfonamide antibiotics inhibit RNAi by binding to human Argonaute protein 2 PAZ.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID409949Inhibition of human liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1682440Binding affinity to human Argonaut protein 2 PAZ domain assessed as change in entropy by isothermal titration microcalorimetry2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Sulfonamide antibiotics inhibit RNAi by binding to human Argonaute protein 2 PAZ.
AID94204Antibacterial activity against Klebsiella pneumoniae at a concentration of 40 ug/mL; no data2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID289689Antibacterial activity against Salmonella enteritidis at 20 mg/ml by paper disc method2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID24211Compound is evaluated for ionization constant log k1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID94206Antibacterial activity against Klebsiella pneumoniae at a concentration of 80 ug/mL; no data2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID40932Antibacterial activity against Bacillus subtilis at a concentration of 40 ug/mL; no data2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID64417Minimum inhibitory concentration (bacteriostatic) against Escherichia coli at pH 7.2 (Sauterne''s medium)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.
AID228124Enzymatic activity was determined1984Journal of medicinal chemistry, Jan, Volume: 27, Issue:1
Parasite enzymes as potential targets for antiparasitic chemotherapy.
AID289691Antibacterial activity against Salmonella enteritidis at 40 mg/ml by paper disc method2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID253057Antibacterial activity of compound against Bacillus subtilis at 20 ug/mL expressed as zone of inhibition2005Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2
QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases.
AID40930Antibacterial activity against Bacillus subtilis at a concentration of 160 ug/mL; no data2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID70304Antibacterial activity against Escherichia coli at a concentration of 20 ug/mL; no data2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID94202Antibacterial activity against Klebsiella pneumoniae at a concentration of 160 ug/mL; no data2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID241574Inhibitory concentration against human cystolic isozyme V of Carbonic anhydrase2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives.
AID55867Inhibition of Escherichia coli (K12J53) Dihydopteroate synthase.1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID289694Antibacterial activity against Pasteurella multocida at40 mg/ml by paper disc method2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Synthesis and biological study of medicinally important Mannich bases derived from 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a pentahydroxy naphthacene carboxamide.
AID215365Inhibitory activity against human trypsin (using Chromozym TH as the substrate)2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Protease inhibitors: synthesis and QSAR study of novel classes of nonbasic thrombin inhibitors incorporating sulfonylguanidine and O-methylsulfonylisourea moieties at P1.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1682441Inhibition of RNAi in human Hela cells expressing Renilla/firefly luciferase genes and siRNA assessed as siRNA-mediated gene silencing activity at 100 to 500 nM by dual luciferase assay relative to control2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Sulfonamide antibiotics inhibit RNAi by binding to human Argonaute protein 2 PAZ.
AID40928Antibacterial activity against Bacillus subtilis at a concentration of 120 ug/mL; no data2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID241604Inhibitory concentration against human cystolic isozyme II of Carbonic anhydrase2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives.
AID1682437Binding affinity to human Argonaut protein 2 PAZ domain assessed as association constant by using isothermal titration microcalorimetry2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Sulfonamide antibiotics inhibit RNAi by binding to human Argonaute protein 2 PAZ.
AID70306Antibacterial activity against Escherichia coli at a concentration of 40 ug/mL; no data2003Bioorganic & medicinal chemistry letters, Nov-03, Volume: 13, Issue:21
QSAR study on antibacterial activity of sulphonamides and derived Mannich bases.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (257)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990193 (75.10)18.7374
1990's6 (2.33)18.2507
2000's19 (7.39)29.6817
2010's24 (9.34)24.3611
2020's15 (5.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.95 (24.57)
Research Supply Index5.63 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index67.64 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.72%)5.53%
Reviews3 (1.08%)6.00%
Case Studies5 (1.81%)4.05%
Observational0 (0.00%)0.25%
Other267 (96.39%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]